PEG-rIL-10 treatment decreases FoxP3+ Tregs despite upregulation of intratumoral IDO. OncoImmunology, Volume 5, 2016 - Issue 7.
IL-10: Expanding the immune oncology horizon. Receptor Clin Invest 2015; 2: e1041. doi: 10.14800/rci.1041.
The Potentiation of IFNγ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells. Journal of Interferon & Cytokine Research, online ahead of print August 26, 2015.
Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunology Research 2(3): 194-199, March 2014.
Pegylated IL-10 induces cancer immunity. Bioessays 35: 623-631, 2013.
IL-10 Elicits IFN-gamma Dependent Tumor Surveilance. Cancer Cell 20: 781-796, December 13, 2011.